Nothing Special   »   [go: up one dir, main page]

WO2017210246A3 - Penicillamine conjugates and particles and formulations thereof - Google Patents

Penicillamine conjugates and particles and formulations thereof Download PDF

Info

Publication number
WO2017210246A3
WO2017210246A3 PCT/US2017/035107 US2017035107W WO2017210246A3 WO 2017210246 A3 WO2017210246 A3 WO 2017210246A3 US 2017035107 W US2017035107 W US 2017035107W WO 2017210246 A3 WO2017210246 A3 WO 2017210246A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
particles
formulations
penicillamine
methods
Prior art date
Application number
PCT/US2017/035107
Other languages
French (fr)
Other versions
WO2017210246A2 (en
Inventor
Brian H. White
Benoît MOREAU
Patrick Rosaire BAZINET
Mark T. Bilodeau
Original Assignee
Tarveda Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarveda Therapeutics, Inc. filed Critical Tarveda Therapeutics, Inc.
Publication of WO2017210246A2 publication Critical patent/WO2017210246A2/en
Publication of WO2017210246A3 publication Critical patent/WO2017210246A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/083—Neurotensin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Conjugates of an active agent attached to a targeting moiety via a penicillamine linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide increased stability and improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
PCT/US2017/035107 2016-05-31 2017-05-31 Penicillamine conjugates and particles and formulations thereof WO2017210246A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662343445P 2016-05-31 2016-05-31
US62/343,445 2016-05-31

Publications (2)

Publication Number Publication Date
WO2017210246A2 WO2017210246A2 (en) 2017-12-07
WO2017210246A3 true WO2017210246A3 (en) 2017-12-28

Family

ID=60479055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/035107 WO2017210246A2 (en) 2016-05-31 2017-05-31 Penicillamine conjugates and particles and formulations thereof

Country Status (1)

Country Link
WO (1) WO2017210246A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL263616B2 (en) 2016-07-07 2025-01-01 Univ Leland Stanford Junior Antibody adjuvant conjugates
EP3723811A4 (en) * 2017-12-14 2021-09-01 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
CN108440664A (en) * 2018-03-27 2018-08-24 上海欣科医药有限公司 A kind of SMS 201-995 and its preparation method and application for cancer detection
JP2022525594A (en) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Immune conjugates targeting HER2
MX2022000474A (en) * 2019-07-11 2022-03-11 Sun Pharma Advanced Res Co Ltd CAMPTOTHECIN DERIVATIVES WITH A DISULFIDE REMAIN AND A PIPERAZINE REMAIN.
WO2022035843A1 (en) * 2020-08-12 2022-02-17 Nanomedicine Innovation Center, Llc Topoisomerase inhibitors
US20230407169A1 (en) * 2020-11-12 2023-12-21 Soochow University Red-light-mediated nucleic acid anchoring-type fluorescent probe, and preparation method therefor and use thereof
CN113307754A (en) * 2021-06-01 2021-08-27 上海吉奉生物科技有限公司 Synthetic method of L-penicillamine hydrochloride

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150283264A1 (en) * 2013-02-07 2015-10-08 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
WO2016004048A2 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150283264A1 (en) * 2013-02-07 2015-10-08 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
WO2016004048A2 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof

Also Published As

Publication number Publication date
WO2017210246A2 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
WO2017210246A3 (en) Penicillamine conjugates and particles and formulations thereof
WO2016004048A3 (en) Targeted conjugates and particles and formulations thereof
MX2019004963A (en) Sstr-targeted conjugates and particles and formulations thereof.
ZA202004099B (en) Methylene carbamate linkers for use with targeted-drug conjugates
MX2015008503A (en) Targeted conjugates encapsulated in particles and formulations thereof.
MX2022001541A (en) Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity.
NZ720743A (en) Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
WO2015095227A3 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
EP4458896A3 (en) Bioorthogonal compositions
WO2016046793A3 (en) Radiopharmaceutical conjugate of a metabolite and an epr agent, for targeting tumour cells
NZ745069A (en) Pyrrolobenzodiazepines and conjugates thereof
PH12017502392A1 (en) Targeted conjugates and particles and formulations thereof
WO2014194030A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
WO2016210376A3 (en) Therapeutic peptides and methods of use thereof
WO2011002852A3 (en) Pro-drug complexes and related methods of use
MX2017015879A (en) Hydroxypropyl beta-cyclodextrin compositions and methods.
WO2015114166A3 (en) Targeted drug conjugates
MX2016009284A (en) Receptor targeting constructs and uses thereof.
WO2010136168A3 (en) Continuous administration of cilengitide in cancer treatments
WO2014134457A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
WO2016130800A3 (en) Pharmaceutical compositions comprising perillyl alcohol derivatives
TN2019000032A1 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
MX2015015434A (en) Targeting corroles for tumor toxicity and mri.
Mulas et al. Current state of the polymeric delivery systems of fluoroquinolones–A review

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17807369

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17807369

Country of ref document: EP

Kind code of ref document: A2